## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.7% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: declining volume (32% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($328.74)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Cencora Bets Big on Oncology Platform in $5 Billion OneOncology Deal**
- Source: MyChesCo | 20251228T030808 | Somewhat-Bullish | Relevance: 100%
- Cencora, Inc. has agreed to acquire the majority of the outstanding equity in OneOncology it does not already own for an equity value of approximately $6 billion and a total cash consideration of roughly $5.0 billion. This acquisition reinforces Cencora's strategy to expand its management services organization in physician-led specialty care, particularly oncology, and is expected to strengthen its specialty solutions and improve patient access to pharmaceuticals and clinical trials. The deal is projected to be neutral to adjusted diluted earnings per share in the first 12 months post-closing and is anticipated to close by the end of Cencora’s fiscal 2026 second quarter.

**2. These 3 Medical Stocks Have Wall Street's Bullish Vote for 2026**
- Source: TradingView — Track All Markets | 20251224T140746 | Bullish | Relevance: 100%
- The medical sector is undergoing a significant transformation, driven by AI, digital therapeutics, and expanding access to care. Despite challenges like cost inflation, demographic trends ensure sustained demand. This article highlights three medical stocks—Cencora (COR), Addus HomeCare (ADUS), and Select Medical Holdings (SEM)—that analysts are bullish on for 2026 due to their strong fundamentals and strategic positioning in the evolving healthcare landscape.

**3. Exchange Traded Concepts LLC Buys 7,924 Shares of Cencora, Inc. $COR**
- Source: MarketBeat | 20251227T090804 | Somewhat-Bullish | Relevance: 100%
- Exchange Traded Concepts LLC significantly increased its stake in Cencora, Inc. (NYSE:COR) by 312.7%, purchasing 7,924 additional shares to hold a total of 10,458 shares valued at $3.27 million. This comes as Cencora reported strong quarterly results, beating EPS and revenue estimates, and raised its FY2026 EPS guidance and quarterly dividend. Several analysts have also increased their price targets for Cencora, contributing to a "Moderate Buy" consensus rating for the company.

**4. Q3 Rundown: Cencora (NYSE:COR) Vs Other Health Insurance Providers Stocks**
- Source: Finviz | 20251224T223600 | Neutral | Relevance: 98%
- This article reviews the Q3 earnings of several health insurance providers, focusing on Cencora (NYSE:COR) and comparing its performance with competitors like CVS Health (NYSE:CVS), Molina Healthcare (NYSE:MOH), UnitedHealth (NYSE:UNH), and Clover Health (NASDAQ:CLOV). It highlights industry trends, regulatory impacts, and the influence of AI while providing a snapshot of each company's revenue, EPS, and stock performance post-earnings.

**5. Cardinal Health (FRA:CLH) EV-to-OCF : 10.24 (As of Dec. 25, 2025)**
- Source: GuruFocus | 20251225T130751 | Neutral | Relevance: 75%
- This article presents Cardinal Health's (FRA:CLH) EV-to-OCF ratio, which stands at 10.24 as of December 25, 2025. It explains the calculation of this metric, detailing that its Enterprise Value is €45,780 Mil and Cash Flow from Operations for the trailing twelve months is €4,469 Mil. The article also provides historical EV-to-OCF data, competitive comparisons within the Medical Distribution industry, and outlines the significance of EV-to-OCF as a valuation multiple.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.81 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $66.2B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.81 |
| Forward P/E | 17.5 |
| Current P/E | 19.5 |
| YoY Growth | 11.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.9% to -1.7% (+1.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.7pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). MACD histogram bearish (-0.67), momentum weakening. RSI neutral at 45. Volume at 32% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.72% (CS: 29) | Neutral |
| RSI_14 | 44.9 | Neutral |
| MACD Histogram | -0.67 | Bearish |
| vs SMA20 | 0.992x | Below |
| vs SMA50 | 0.982x | Below |
| vs SMA200 | 1.119x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $341.12
- **Stop Loss:** $328.74 (3.6% risk)
- **Target:** $353.50 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 106
- **Position Value:** $36,158.72
- **Portfolio %:** 36.16%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*